FDA Approves La Jolla Pharmaceutical's (LJPC) Giapreza for Dangerously Low Blood Pressure
Tweet Send to a Friend
The U.S. Food and Drug Administration today approved La Jolla Pharmaceutical's (NASDAQ: LJPC) Giapreza (angiotensin II) injection for intravenous infusion ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE